Labour induction for termination of pregnancy with severe fetal anomalies after 24 weeks’ gestation: a case series and systematic review of the literature

Kiley, Jessica; Turner, Ashley M; Nosal, Catherine; Beestrum, Molly; Dungan, J.S.

doi:10.1080/13625187.2022.2102604

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported [14] that combined mifepristone-misoprostol could resulted in shorter induction-to-delivery intervals for the second trimester induce of labour(IOL), compared with the using of sulprostone, and in this study, they also reported cases of third-trimester stillbirth induction, whey all received misoprostol alone. Until now, the current literature on mifepristone-misoprostol using in the third trimester remains limited, compared with that in the second trimester, and few studies specified the actual number of patients in the third trimester, and future research is necessary on third-trimester outcomes with mifepristone-misoprostol [15].…”

Section: Discussionmentioning

confidence: 99%

Mifepristone combined with ethacridine lactate for third-trimester stillbirth induction: a 5-year experience from Shanghai

Xue

Yao

et al. 2022

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Objective To review and analyze the efficacy and safety of mifepristone combined with ethacridine lactate for induction of stillbirth in the third trimester. Methods All patients with stillbirth in late pregnancy (≥ 28 weeks) in a university-affiliated maternity center from October 2016 to September 2021 were included in this study. After exclusion, patients were divided into ethacridine lactate and non-ethacridine lactate groups according to induction methods. Logistic regression was conducted to identify the risks of complications. Results We identified 122 patients that experienced stillbirth (5’ Apgar score = 0) in third-trimester from the 5-year total deliveries in the hospital, among whom 39 stillbirths that resulted from termination of pregnancy for severe fetal anomalies and 1 stillbirth that was in twin pregnancy were excluded. Thus, 82 cases with stillbirths (dead before induction) were included in the analyses. In the 82 cases, 49 (59.76%) accepted intra-amniotic ethacridine lactate induction with 47 (95.92%, 47/49) successfully induced. No statistical difference was observed in induction failure rate between ethacridine dosage groups of < 75mg and ≥ 75mg (0/25, vs. 2/24, respectively; P > 0.05). The ethacridine lactate induction group showed no increased risks in complications (6.12%, 3/49), compared with non-ethacridine lactate group (12.12%, 4/33) (P = 0.35, OR, 0.47, 95%CI, 0.10 to 2.27). Conclusion Mifepristone combined with ethacridine lactate is a safe and low-risk induction method for patients with stillbirth in the third trimester.

show abstract

Section: Discussionmentioning

confidence: 99%